Vanguard Group Inc. Buys 77,451 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Vanguard Group Inc. boosted its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 1.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,440,005 shares of the medical device company's stock after purchasing an additional 77,451 shares during the period. Vanguard Group Inc. owned about 11.33% of Tandem Diabetes Care worth $267,989,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in TNDM. JPMorgan Chase & Co. lifted its holdings in shares of Tandem Diabetes Care by 134.6% in the third quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company's stock worth $8,379,000 after buying an additional 113,355 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in Tandem Diabetes Care by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 37,422 shares of the medical device company's stock valued at $1,587,000 after buying an additional 21,086 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after purchasing an additional 1,101 shares in the last quarter. US Bancorp DE lifted its position in shares of Tandem Diabetes Care by 15.2% in the 4th quarter. US Bancorp DE now owns 38,708 shares of the medical device company's stock worth $1,394,000 after purchasing an additional 5,108 shares during the period. Finally, KBC Group NV raised its position in shares of Tandem Diabetes Care by 41.5% in the 4th quarter. KBC Group NV now owns 192,479 shares of the medical device company's stock worth $6,933,000 after acquiring an additional 56,461 shares in the last quarter.

Wall Street Analysts Forecast Growth

TNDM has been the subject of several research reports. The Goldman Sachs Group lowered their price objective on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Royal Bank of Canada dropped their target price on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a research report on Thursday, February 27th. Robert W. Baird lowered their target price on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating on the stock in a research note on Thursday, February 27th. Wells Fargo & Company reissued an "equal weight" rating and set a $22.00 price objective (down previously from $38.00) on shares of Tandem Diabetes Care in a research note on Monday, March 3rd. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $63.00 price objective on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Eight research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, Tandem Diabetes Care presently has an average rating of "Moderate Buy" and a consensus target price of $45.38.

Tandem Diabetes Care Stock Up 7.6 %

Tandem Diabetes Care stock traded up $1.24 during midday trading on Wednesday, reaching $17.61. The stock had a trading volume of 3,037,951 shares, compared to its average volume of 1,492,696. The company has a fifty day moving average price of $25.16 and a two-hundred day moving average price of $31.59. The company has a market capitalization of $1.17 billion, a P/E ratio of -9.12 and a beta of 1.52. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 12 month low of $15.75 and a 12 month high of $53.69.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos acquired 10,538 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares of the company's stock, valued at approximately $190,948.56. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.20% of the stock is currently owned by company insiders.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.